TG Therapeutics, Inc.
TGTX
|
$13.79
-1.43%
-1.45%
3.7M
|
Health Technology
(0.0% 1d) (-9.6% 1m) (-37.8% 1y) (-1.5% 2d) (-1.9% 3d) (-2.1% 7d) (5.23% volume)
Earnings Calendar: 2023-11-08
Market Cap: $ 2,129,462,446
http://www.tgtherapeutics.com
Sec Filling | Patents | 134 employees
(US) TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.
acquisitions autoimmunity t-cell treatment ceiling
Drugs
UKONIQ (umbralisib)add to watch list Paper trade email alert is off
Press-releases
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
Published: 2024-04-18 (Crawled : 12:00) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: -0.43%
H: 4.57%
C: 0.0%
briumvi neurology sclerosis for meeting therapeutics
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: -0.43%
H: 4.57%
C: 0.0%
cd20 briumvi contract sclerosis for therapeutics
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: -3.94%
H: 3.0%
C: -0.57%
briumvi neurology presentation sclerosis for meeting therapeutics
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
Published: 2024-03-27 (Crawled : 11:00) - biospace.com/
CRBU | $3.87 -1.02% -1.03% 1.7M
|
Health Technology
|
| O: 1.58%
H: 0.58%
C: -0.39%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.24%
H: 0.42%
C: 0.4%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.49%
H: 0.84%
C: -0.07%
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: 0.71%
H: 0.39%
C: 0.13%
DTIL | $9.75 -9.05% -9.95% 170K
|
Health Technology
|
| O: 0.39%
H: 4.22%
C: 1.41%
precision business year update financial results
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
Published: 2024-03-08 (Crawled : 12:30) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: 1.17%
H: 0.44%
C: -7.85%
briumvi sclerosis meeting therapeutics
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
Published: 2024-03-01 (Crawled : 12:30) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: 1.86%
H: 4.79%
C: 2.39%
briumvi presentation sclerosis treatment research therapeutics
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results
Published: 2024-02-28 (Crawled : 12:00) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: 16.32%
H: 16.75%
C: 8.96%
business update therapeutics financial results
TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)
Published: 2024-02-27 (Crawled : 12:30) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: 3.44%
H: 1.77%
C: 0.65%
briumvi therapeutics
TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)Newly issued patents extend exclusivity of ublituximab through 2042
Published: 2024-02-27 (Crawled : 14:30) - biospace.com/
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: 3.44%
H: 1.77%
C: 0.65%
briumvi therapeutics
TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy)
Published: 2024-02-26 (Crawled : 12:00) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: 1.35%
H: 1.67%
C: -1.04%
briumvi therapeutics
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
KUKE | $2.88 2.49% 7.64% 360K
|
CXM 4 | $11.34 -0.44% 4.27% 1.7M
|
Information
PVL 4 | $1.47 -0.68% 4.08% 77K
|
Energy Minerals
RNR 4 | $224.74 0.85% 3.52% 310K
|
Finance
PZG | $0.4431 0.48% 2.91% 150K
|
Non-Energy Minerals
SIX | $23.45 -0.55% 0.68% 650K
|
Consumer Services
NEWP | $1.97 0.61% 310K
|
Mining, Quarrying, and Oil and ...
KNSL 4 | $451.81 -0.02% 0.49% 140K
|
Finance
SENS | $0.3992 -4.04% 0.45% 2M
|
Electronic Technology
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10